Compare StocksADI vs PFE

Analog Devices, Inc. (ADI) vs Pfizer Inc. (PFE): Which Is the Better Buy in 2026?

As of 2026-06-19, ADI is overvalued at $434, with a DCF intrinsic value of $345 and a margin of safety of -26%. PFE is overvalued at $25, with an intrinsic value of $22 and a margin of safety of -12%. Of the two, PFE has the wider margin of safety.

ADI
Analog Devices, Inc.
$434.46
VS
PFE
Pfizer Inc.
$25.21

Rewards

ADI
  • Gross margin of 64.5% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • PEG ratio of 0.91 suggests the stock is undervalued relative to its growth rate — paying less than 1x for each unit of earnings growth.
  • Altman Z-Score of 6.46 indicates very low bankruptcy risk — the company is firmly in the safe zone.
PFE
  • Gross margin of 74.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • FCF yield of 8.6% is historically attractive — the business generates significant cash relative to its price.
  • Trailing P/E of 19.2x is 37% below the historical average of 30.4x — potentially undervalued relative to its own history.

Risks

ADI
  • FCF yield of 1.8% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
  • Trailing P/E of 64.5x is 40% above the historical average of 46.1x — the stock trades at a premium to its own history.
  • 7 insider sales totaling $43.9M with no purchases in the past 3 months — insiders are reducing their exposure.
PFE
  • ROIC has declined by 15.9 percentage points over the past 4 years, which may signal competitive erosion.
  • PEG ratio of 13.77 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • Free cash flow has declined at a 29.6% CAGR over the past 4 years — a concerning trend.

Key Valuation Metrics

Learn more →
ADI
PFE
Valuation
$3.87B
Free Cash Flow
$12.38B
1.83%
FCF Yield
8.61%
64.46
Trailing P/E
19.24
29.41
Forward P/E
8.91
Quality & Moat
9.03%
ROIC
10.19%
9.64%
ROE
8.31%
64.49%
Gross Margin
74.80%
0.91
PEG Ratio
13.77
Balance Sheet Safety
0.16
Net Debt / Equity
0.57
N/A
Interest Coverage
N/A
0.86
Net Debt / EBITDA
2.03
1.01%
Dividend Yield
6.61%
ADI: 4Ties: 1PFE: 7
ADIPFE

Historical Fundamentals

Learn more →
ADI

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

PFE

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ADI
$27.09
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$1.82B
Δ Market Cap
+$49.25B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
PFE
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-10.61B
Δ Market Cap
$-146.18B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ADI
36.7% Overvalued
Price is 36.7% above estimated fair value
Current Price: $434.46
Fair Value: $317.89
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
PFE
12.3% Overvalued
Price is 12.3% above estimated fair value
Current Price: $25.21
Fair Value: $22.46
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ADI

What growth rate is the market pricing in at $434?

+22.3%
Market-Implied Owner Earnings Growth
Standard FCF implies +21.8%

The market implies +22.3% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +21.8%, reflecting heavy growth investment.

PFE

What growth rate is the market pricing in at $25?

+5.2%
Market-Implied Owner Earnings Growth
Standard FCF implies +4.5%

The market implies +5.2% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +4.5%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ADI
36/100
No Moat
70+ Wide · 40-69 Narrow · <40 None

No durable moat detected, though reinvestment efficiency shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
PFE
35/100
No Moat
70+ Wide · 40-69 Narrow · <40 None

No durable moat detected, though reinvestment efficiency shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
ADI
-2.75
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
PFE
-2.53
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ADI
Insiders 0.2%Institutions 93.5%Retail & Other 6.2%
No. of Institutional Holders2,790
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
PFE
Insiders 0.1%Institutions 69.4%Retail & Other 30.5%
No. of Institutional Holders3,744
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ADI
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
PFE
0
Buys (3M)
0
Buys (12M)
BLAYLOCK RONALD E
Director
$499,072
@ $25.65 · 2025-02-13
GOTTLIEB SCOTT
Director
$28,240
@ $28.24 · 2024-10-30
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ADI
7
Sells (3M)
33
Sells (12M)
Total value (12M): $92.01M
GOLZ KAREN M.
Director
$411,950
@ $411.95 · 2026-06-12
STATA RAYMOND S
Director
$573,982
@ $400.83 · 2026-06-09
COTTER MARTIN
Officer
$7.35M
@ $418.00 · 2026-06-02
ROCHE VINCENT T
Chief Executive Officer
$4.04M
@ $404.25 · 2026-06-01
ROCHE VINCENT T
Chief Executive Officer
$24.36M
@ $405.97 · 2026-05-26
ROCHE VINCENT T
Chief Executive Officer
$3.98M
@ $397.91 · 2026-05-01
ROCHE VINCENT T
Chief Executive Officer
$3.18M
@ $318.14 · 2026-04-01
STATA RAYMOND S
Director
$2.00M
@ $319.40 · 2026-03-11
ROCHE VINCENT T
Chief Executive Officer
$3.50M
@ $350.00 · 2026-03-02
SONDEL MICHAEL
Officer
$1.52M
@ $361.11 · 2026-02-25
STATA RAYMOND S
Director
$2.00M
@ $319.39 · 2026-02-05
ROCHE VINCENT T
Chief Executive Officer
$3.07M
@ $306.92 · 2026-02-02
STATA RAYMOND S
Director
$1.85M
@ $296.44 · 2026-01-14
NAKAMURA KATSUFUMI
Officer
$150,732
@ $301.46 · 2026-01-09
NAKAMURA KATSUFUMI
Officer
$144,582
@ $289.16 · 2026-01-07
COTTER MARTIN
Officer
$2.78M
@ $278.44 · 2026-01-05
ROCHE VINCENT T
Chief Executive Officer
$2.75M
@ $275.07 · 2026-01-02
COTTER MARTIN
Officer
$1.36M
@ $271.19 · 2025-12-17
STATA RAYMOND S
Director
$1.73M
@ $276.45 · 2025-12-17
ROCHE VINCENT T
Chief Executive Officer
$2.82M
@ $282.42 · 2025-12-12
SONDEL MICHAEL
Officer
$2.28M
@ $279.50 · 2025-12-10
JAIN VIVEK
Officer
$1.57M
@ $265.88 · 2025-12-01
STATA RAYMOND S
Director
$1.46M
@ $232.86 · 2025-11-05
ROCHE VINCENT T
Chief Executive Officer
$2.35M
@ $234.95 · 2025-11-03
FRANK EDWARD H
Director
$242,740
@ $242.74 · 2025-10-06
STATA RAYMOND S
Director
$1.51M
@ $241.64 · 2025-10-02
ROCHE VINCENT T
Chief Executive Officer
$2.44M
@ $243.71 · 2025-10-01
STATA RAYMOND S
Director
$1.55M
@ $248.27 · 2025-09-18
COTTER MARTIN
Officer
$3.08M
@ $246.25 · 2025-09-05
ROCHE VINCENT T
Chief Executive Officer
$2.46M
@ $246.50 · 2025-09-02
NAKAMURA KATSUFUMI
Officer
$617,595
@ $248.03 · 2025-08-21
STATA RAYMOND S
Director
$1.38M
@ $220.64 · 2025-08-06
STATA RAYMOND S
Director
$1.50M
@ $240.13 · 2025-07-17
STATA RAYMOND S
Director
$1.45M
@ $232.57 · 2025-06-12
STATA RAYMOND S
Director
$1.23M
@ $196.86 · 2025-05-07
ROCHE VINCENT T
Chief Executive Officer
$1.97M
@ $196.84 · 2025-05-01
STATA RAYMOND S
Director
$1.11M
@ $177.49 · 2025-04-16
ROCHE VINCENT T
Chief Executive Officer
$2.00M
@ $200.26 · 2025-04-01
JAIN VIVEK
Officer
$2.66M
@ $210.00 · 2025-03-24
PUCCIO RICHARD C. JR.
Chief Financial Officer
$836,760
@ $209.19 · 2025-03-19
ROCHE VINCENT T
Chief Executive Officer
$2.09M
@ $209.12 · 2025-03-12
ROCHE VINCENT T
Chief Executive Officer
$2.10M
@ $210.44 · 2025-03-11
JOHNSON MERCEDES
Director
$1.36M
@ $227.12 · 2025-03-05
STATA RAYMOND S
Director
$469,920
@ $224.52 · 2025-03-05
ROCHE VINCENT T
Chief Executive Officer
$2.33M
@ $232.62 · 2025-03-03
ROCHE VINCENT T
Chief Executive Officer
$2.35M
@ $234.82 · 2025-02-26
ROCHE VINCENT T
Chief Executive Officer
$2.15M
@ $215.49 · 2025-01-02
ROCHE VINCENT T
Chief Executive Officer
$2.16M
@ $215.83 · 2024-12-11
BRYANT GREGORY M.
Officer
$4.48M
@ $223.87 · 2024-11-01
ROCHE VINCENT T
Chief Executive Officer
$2.24M
@ $223.87 · 2024-11-01
ROCHE VINCENT T
Chief Executive Officer
$2.29M
@ $228.93 · 2024-10-01
BRYANT GREGORY M.
Officer
$6.87M
@ $228.93 · 2024-10-01
BRYANT GREGORY M.
Officer
$6.72M
@ $224.10 · 2024-09-25
ROCHE VINCENT T
Chief Executive Officer
$2.29M
@ $228.69 · 2024-09-03
FRANK EDWARD H
Director
$233,133
@ $234.30 · 2024-08-29
FRANK EDWARD H
Director
$113,618
@ $227.24 · 2024-08-23
ROCHE VINCENT T
Chief Executive Officer
$2.28M
@ $228.08 · 2024-08-01
ROCHE VINCENT T
Chief Executive Officer
$2.27M
@ $226.70 · 2024-07-01
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
PFE
1
Sells (3M)
1
Sells (12M)
Total value (12M): $51,400
DAMICO JENNIFER B.
Officer
$51,400
@ $25.70 · 2026-06-09
DAMICO JENNIFER B.
Officer
$64,825
@ $25.93 · 2025-03-04
DAMICO JENNIFER B.
Officer
$147,714
@ $28.66 · 2024-08-13
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ADI
FearGreed
😏Greed(64/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
PFE
FearGreed
😐Neutral(49/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ADI
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (64)
PFE
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (49)
View ADI Full AnalysisView PFE Full Analysis

Frequently Asked Questions: ADI vs PFE

Is Analog Devices, Inc. or Pfizer Inc. more undervalued in 2026?

Based on our discounted cash flow model, PFE trades at a -12.3% margin of safety (intrinsic value $22 vs. price $25), compared to ADI's -26.0% margin of safety (intrinsic $345 vs. $434).

Which stock has a wider economic moat, Analog Devices, Inc. or Pfizer Inc.?

ADI scores 36/100 (None moat), while PFE scores 35/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is Pfizer Inc. in financial distress?

PFE's Altman Z-Score of 2.1 places it in the Grey zone, signaling elevated bankruptcy risk. ADI scores 6.5 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, Analog Devices, Inc. or Pfizer Inc.?

Pfizer Inc. (PFE) generates a 8.6% free cash flow yield, compared to Analog Devices, Inc.'s 1.8%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, Analog Devices, Inc. or Pfizer Inc.?

PFE earns 10.2% ROIC versus ADI's 9.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, Analog Devices, Inc.'s or Pfizer Inc.'s?

ADI's dividend earns a safety score of 64/100 (Safe), compared to PFE's 24/100 (Unsafe). ADI has raised its dividend for 3 consecutive years.